Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
10:57am, Wednesday, 25'th Jan 2023 The Motley Fool
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
10:45pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
Eli Lilly (LLY) closed at $346.39 in the latest trading session, marking a +1.22% move from the prior day.
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
02:30pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommenda
Eli Lilly to invest additional $450 million in Research Triangle Park facility, to add at least 100 jobs
06:42am, Tuesday, 24'th Jan 2023
Eli Lilly & Co. LLY, -1.12% said Tuesday it's planning to invest an additional $450 million in a manufacturing site at Research Triangle Park in North Carolina and will create at least 100 jobs. The n
Jim Cramer says there's a buying opportunity in this pharmaceutical company
07:55pm, Monday, 23'rd Jan 2023
Cramer gave his take on why investors should consider picking up shares of Eli Lilly.
Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance
03:38pm, Monday, 23'rd Jan 2023 Zacks Investment Research
Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
02:38pm, Monday, 23'rd Jan 2023 Zacks Investment Research
Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.
Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance
12:03pm, Monday, 23'rd Jan 2023
Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
3 Drug Stocks With Promising Pipelines for 2023
10:03am, Monday, 23'rd Jan 2023
The world of pharmaceutical progress happens incrementally and exponentially. That is, therapies are iteratively improved while breakthrough treatments are also created and discovered.
Lilly's Alzheimer's drug setback is ‘not a thesis-breaker'
02:44pm, Saturday, 21'st Jan 2023
Eli Lilly & Co (NYSE: LLY) ended slightly down on Friday after the U.S. FDA rejected its request of accelerated approval for Donanemab – its Alzheimer's drug. Why did the FDA reject its application?
Why the FDA didn't grant an approval to Lilly's Alzheimer's drug
02:19pm, Saturday, 21'st Jan 2023 MarketWatch
The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year
S&P 500, Dow score best day in 2 weeks, Nasdaq erases weekly loss as Netflix, Alphabet jump
09:48pm, Friday, 20'th Jan 2023 MarketWatch
U.S. stocks end sharply higher Friday, but the S&P 500 and Dow still booked weekly losses.
US Markets End the Week With Gains as Tech Stocks Soar
06:10pm, Friday, 20'th Jan 2023
The Nasdaq was up by roughly 2.7% during the session on Friday, Jan. 20, while the Dow and S&P 500 also posted gains to close out the trading week.
FDA rejects Eli Lilly's accelerated approval application for Alzheimer's drug
05:56pm, Friday, 20'th Jan 2023
Yahoo Finance Live anchors Dave Briggs and Seana Smith discuss the move lower in Eli Lilly stock.
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
05:52pm, Friday, 20'th Jan 2023 Zacks Investment Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
